Latest & greatest articles for clopidogrel

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on clopidogrel or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on clopidogrel and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for clopidogrel

101. Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. Full Text available with Trip Pro

Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. To evaluate efficacy and safety outcomes in patients in the PLATelet inhibition and patient Outcomes (PLATO) trial who at randomisation were planned for a non-invasive treatment strategy.Pre-specified analysis of pre-randomisation defined subgroup of prospective randomised clinical trial.862 (...) centres in 43 countries.5216 (28%) of 18,624 patients admitted to hospital for acute coronary syndrome who were specified as planned for non-invasive management.Randomised treatment with ticagrelor (n=2601) versus clopidogrel (2615).Primary composite end point of cardiovascular death, myocardial infarction, and stroke; their individual components; and PLATO defined major bleeding during one year.2183 (41.9%) patients had coronary angiography during their initial hospital admission, 1065 (20.4%) had

2011 BMJ Controlled trial quality: predicted high

102. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. Full Text available with Trip Pro

Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. High platelet reactivity while receiving clopidogrel has been linked to cardiovascular events after percutaneous coronary intervention (PCI), but a treatment strategy for this issue is not well defined.To evaluate the effect of high-dose compared with standard-dose clopidogrel in patients with high on-treatment platelet reactivity after PCI.Randomized (...) , double-blind, active-control trial (Gauging Responsiveness with A VerifyNow assay-Impact on Thrombosis And Safety [GRAVITAS]) of 2214 patients with high on-treatment reactivity 12 to 24 hours after PCI with drug-eluting stents at 83 centers in North America between July 2008 and April 2010.High-dose clopidogrel (600-mg initial dose, 150 mg daily thereafter) or standard-dose clopidogrel (no additional loading dose, 75 mg daily) for 6 months.The primary end point was the 6-month incidence of death from

2011 JAMA Controlled trial quality: predicted high

103. Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial Full Text available with Trip Pro

Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial Dual antiplatelet therapy with clopidogrel plus acetylsalicylic acid (ASA) is superior to ASA alone in patients with acute coronary syndromes and in those undergoing percutaneous coronary intervention. We sought to determine whether clopidogrel plus ASA conferred benefit on limb outcomes over ASA alone in patients undergoing below-knee bypass (...) grafting.Patients undergoing unilateral, below-knee bypass graft for atherosclerotic peripheral arterial disease (PAD) were enrolled 2 to 4 days after surgery and were randomly assigned to clopidogrel 75 mg/day plus ASA 75 to 100 mg/day or placebo plus ASA 75 to 100 mg/day for 6 to 24 months. The primary efficacy endpoint was a composite of index-graft occlusion or revascularization, above-ankle amputation of the affected limb, or death. The primary safety endpoint was severe bleeding (Global Utilization

2010 EvidenceUpdates Controlled trial quality: predicted high

104. Interaction of clopidogrel and omeprazole. (Abstract)

Interaction of clopidogrel and omeprazole. 21067412 2010 11 30 2018 12 01 1533-4406 363 20 2010 Nov 11 The New England journal of medicine N. Engl. J. Med. Interaction of clopidogrel and omeprazole. 1977 10.1056/NEJMc1012022 Southworth Mary Ross MR Temple Robert R eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Platelet Aggregation Inhibitors 0 Proton Pump Inhibitors A74586SNO7 Clopidogrel KG60484QX9 Omeprazole OM90ZUW7M1 Ticlopidine AIM IM N Engl J Med. 2010 Nov 11;363(20 (...) ):1909-17 20925534 Cardiovascular Diseases epidemiology prevention & control Clopidogrel Coronary Artery Disease drug therapy Drug Interactions Drug Therapy, Combination Gastrointestinal Hemorrhage prevention & control Humans Omeprazole pharmacology therapeutic use Platelet Aggregation Inhibitors therapeutic use Proton Pump Inhibitors pharmacology therapeutic use Ticlopidine analogs & derivatives therapeutic use 2010 11 12 6 0 2010 11 12 6 0 2010 12 14 6 0 ppublish 21067412 10.1056/NEJMc1012022

2010 NEJM

105. Effect of clopidogrel on the rate and functional severity of stroke among high vascular risk patients: a prespecified substudy of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) trial Full Text available with Trip Pro

Effect of clopidogrel on the rate and functional severity of stroke among high vascular risk patients: a prespecified substudy of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) trial Disabling stroke is costly and considered by some patients a fate worse than death. We aimed to determine whether clopidogrel reduces the rate and functional severity of stroke among high vascular risk patients, including patients with previous (...) transient ischemic attack or ischemic stroke, who were enrolled in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) trial.We randomly assigned 15,603 high vascular risk patients to receive clopidogrel (75 mg daily) or placebo in addition to background acetylsalicylic acid and followed them for a median of 28 months. The main outcome of this prespecified substudy was the functional severity of stroke outcome events as measured by the modified

2010 EvidenceUpdates Controlled trial quality: predicted high

106. Clopidogrel (Plavix) and Proton Pump Inhibitors: An Update on the Potential Drug Interaction

Clopidogrel (Plavix) and Proton Pump Inhibitors: An Update on the Potential Drug Interaction Clopidogrel (Plavix®) and Proton Pump Inhibitors: An Update on the Potential Drug Interaction – Clinical Correlations Search Clopidogrel (Plavix®) and Proton Pump Inhibitors: An Update on the Potential Drug Interaction July 28, 2010 5 min read By Antony Q. Pham, Pharm.D. and Reena M. Tejura, Pharm.D. Faculty Peer Reviewed Recent publications have described a potential drug interaction between (...) clopidogrel (Plavix®) and proton pump inhibitors (PPIs). Several retrospective studies have concluded that the use of PPIs can lower the effectiveness of clopidogrel and as a result, increase the possibility of cardiovascular events. Limited data from prospective trials have yet to show a clinical significance from this potential interaction. The Food and Drug Administration (FDA) released an early communication about the ongoing safety review of clopidogrel and omeprazole on January 26, 2009. Over

2010 Clinical Correlations

107. Duration of clopidogrel therapy with drug-eluting stents. Full Text available with Trip Pro

Duration of clopidogrel therapy with drug-eluting stents. 20666628 2010 09 10 2018 12 01 1533-4406 363 5 2010 07 29 The New England journal of medicine N. Engl. J. Med. Duration of clopidogrel therapy with drug-eluting stents. 488; author reply 490 10.1056/NEJMc1005624 Okura Hiroyuki H eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Platelet Aggregation Inhibitors A74586SNO7 Clopidogrel OM90ZUW7M1 Ticlopidine R16CO5Y76E Aspirin AIM IM N Engl J Med. 2010 Apr 15;362(15):1374-82 (...) 20231231 Angioplasty, Balloon, Coronary Aspirin administration & dosage Clopidogrel Coronary Disease mortality therapy Drug Administration Schedule Drug Therapy, Combination Drug-Eluting Stents Humans Myocardial Infarction epidemiology Platelet Aggregation Inhibitors administration & dosage Stroke epidemiology Ticlopidine administration & dosage analogs & derivatives 2010 7 30 6 0 2010 7 30 6 0 2010 9 11 6 0 ppublish 20666628 10.1056/NEJMc1005624 10.1056/NEJMc1005624#SA1

2010 NEJM

108. Risk of adverse outcomes in Taiwan associated with concomitant use of clopidogrel and proton pump inhibitors in patients who received percutaneous coronary intervention (Abstract)

Risk of adverse outcomes in Taiwan associated with concomitant use of clopidogrel and proton pump inhibitors in patients who received percutaneous coronary intervention Recent studies have suggested that proton pump inhibitors (PPIs) might reduce the inhibitory effect of clopidogrel on platelet aggregation, possibly through inhibition of the hepatic cytochrome P450 2C19 (CYP2C19) isoenzyme. The prevalence of CYP2C19 loss-of-function alleles is much greater among East Asians than among other (...) populations. Thus, potential drug interactions might be more apparent. Therefore, we conducted a nationwide, population-based study using the Taiwan National Health Insurance database. We identified 3,278 patients (mean age 65.9 +/- 11.9 years, 71.9% men) with coronary artery disease who had taken clopidogrel after percutaneous coronary intervention from the 1 million sampling cohort data set since January 1, 2002. Of the 3,278 patients, 572 had received concomitant PPIs for underlying gastrointestinal

2010 EvidenceUpdates

109. Incidence of Dyspnea and Assessment of Cardiac and Pulmonary Function in Patients With Stable Coronary Artery Disease Receiving Ticagrelor, Clopidogrel, or Placebo in the ONSET/OFFSET Study Full Text available with Trip Pro

Incidence of Dyspnea and Assessment of Cardiac and Pulmonary Function in Patients With Stable Coronary Artery Disease Receiving Ticagrelor, Clopidogrel, or Placebo in the ONSET/OFFSET Study We prospectively assessed cardiac and pulmonary function in patients with stable coronary artery disease (CAD) treated with ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET (A Multi-Centre Randomised, Double-Blind, Double-Dummy Parallel Group Study of the Onset and Offset of Antiplatelet Effects (...) of AZD6140 Compared With Clopidogrel and Placebo With Aspirin as Background Therapy in Patients With Stable Coronary Artery Disease) study.Ticagrelor reduces cardiovascular events more effectively than clopidogrel in patients with acute coronary syndromes. Dyspnea develops in some patients treated with ticagrelor, and it is not known whether this is associated with changes in cardiac or pulmonary function.In all, 123 stable aspirin-treated CAD patients randomly received either ticagrelor (180 mg load

2010 EvidenceUpdates Controlled trial quality: predicted high

110. Adding clopidogrel to standard therapy for acute myocardial infarction.

Adding clopidogrel to standard therapy for acute myocardial infarction. BestBets: Adding clopidogrel to standard therapy for acute myocardial infarction. Adding clopidogrel to standard therapy for acute myocardial infarction. Report By: Kate Rotheray - Visiting Scholar Search checked by Giles Cattermole - Assistant Professor Institution: Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong Date Submitted: 22nd October 2009 Date Completed: 23rd March 2010 Last Modified: 14th (...) April 2010 Status: Green (complete) Three Part Question In [patients with acute ST-elevation MI] is [clopidogrel plus aspirin better than aspirin alone] at [reducing morbidity and mortality]? Clinical Scenario A 60 year old man presents to the Emergency Department (ED) with chest pain. The ECG shows an ST elevation MI. You give him oxygen, nitrates, aspirin and morphine and also start thrombolysis. You wonder whether giving him clopidogrel as well would be beneficial. Search Strategy (OVID interface

2010 BestBETS

111. When Clopidogrel Fails…

When Clopidogrel Fails… When Clopidogrel Fails… – Clinical Correlations Search When Clopidogrel Fails… March 10, 2010 3 min read Marisa Mizus Faculty peer reviewed Clopidogrel ( Plavix ) has been the standard of care for patients with coronary artery disease following percutaneous coronary intervention (PCI) for the past decade. Although it is a successful antiplatelet treatment in many patients, like any hero, it has a weakness: formation of its active metabolite depends on two hepatic (...) cytochrome P450 (CYP450)-dependent steps. Clopidogrel resistance, or non-response, is correlated with an increased risk of major adverse cardiovascular events, including reinfarction and stent thrombosis.(1) It is often unclear why a patient does not respond to clopidogrel, although there is speculation that clopidogrel resistance results from the attenuating effects of proton pump inhibitors (PPIs) and CYP450 reduced function polymorphisms.(2) Patients showing inadequate platelet response to clopidogrel

2010 Clinical Correlations

112. Cost-Effectiveness of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndromes and Planned Percutaneous Coronary Intervention. Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38 Full Text available with Trip Pro

Cost-Effectiveness of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndromes and Planned Percutaneous Coronary Intervention. Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38 In patients with acute coronary syndromes and planned percutaneous coronary intervention, the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38 (...) ) demonstrated that treatment with prasugrel versus clopidogrel was associated with reduced rates of cardiovascular death, MI, or stroke and an increased risk of major bleeding. We evaluated the cost-effectiveness of prasugrel versus clopidogrel from the perspective of the US healthcare system by using data from TRITON-TIMI 38.Detailed resource use data were prospectively collected for all patients recruited from 8 countries (United States, Australia, Canada, Germany, Italy, Spain, United Kingdom, and France

2010 EvidenceUpdates

113. DuoPlavin - clopidogrel / acetylsalicylic acid

DuoPlavin - clopidogrel / acetylsalicylic acid European Medicines Agency 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 86 13 E-mail: mail@ema.europa.eu http://www.ema.europa.eu London, 17 December 2009 Doc. Ref: EMA/CHMP/196090/2010 CHMP ASSESSMENT REPORT FOR DuoPlavin International Nonproprietary Name: clopidogrel / acetylsalicylic acid Procedure No. EMEA/H/C/001143 TABLE OF CONTENTS 1. BACKGROUND INFORMATION ON THE PROCEDURE 3 1.1 Submission (...) for the following indication: DuoPlavin is indicated for the prevention of atherothrombotic events in adult patients already taking both clopidogrel and acetylsalicylic acid (ASA). DuoPlavin is a fixed-dose combination product for continuation of therapy in: ? Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction) including patients undergoing a stent placement following percutaneous coronary intervention ? ST segment elevation acute myocardial infarction

2010 European Medicines Agency - EPARs

114. DuoCover - clopidogrel / acetylsalicylic acid

DuoCover - clopidogrel / acetylsalicylic acid European Medicines Agency 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 86 13 E-mail: mail@ema.europa.eu http://www.ema.europa.eu London, 17 December 2009 Doc. Ref: EMA/CHMP/195986/2010 CHMP ASSESSMENT REPORT FOR DuoCover International Nonproprietary Name: clopidogrel / acetylsalicylic acid Procedure No. EMEA/H/C/001144 TABLE OF CONTENTS 1. BACKGROUND INFORMATION ON THE PROCEDURE 3 1.1 Submission (...) indication: DuoCover is indicated for the prevention of atherothrombotic events in adult patients already taking both clopidogrel and acetylsalicylic acid (ASA). DuoCover is a fixed-dose combination product for continuation of therapy in: ? Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction) including patients undergoing a stent placement following percutaneous coronary intervention ? ST segment elevation acute myocardial infarction in medically treated

2010 European Medicines Agency - EPARs

115. Clopidogrel in the treatment of non-ST-segment-elevation acute coronary syndrome (TA80)

Clopidogrel in the treatment of non-ST-segment-elevation acute coronary syndrome (TA80) Clopidogrel in the treatment of non-ST-segment-elevation acute coronary syndrome | Guidance | NICE Clopidogrel in the treatment of non-ST-segment-elevation acute coronary syndrome Technology appraisal guidance [TA80] Published date: 28 July 2004 Guidance This guidance has been replaced by recommendations 1.3.4 to 1.3.8 in and by recommendation 1.3.18 in . Explore © NICE [year]. All rights reserved. Subject to .

2010 National Institute for Health and Clinical Excellence - Technology Appraisals

116. Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (TA210)

Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (TA210) Overview | Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events | Guidance | NICE Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events Technology appraisal guidance [TA210] Published date: 15 December 2010 Share Guidance on clopidogrel and modified-release dipyridamole for preventing occlusive vascular events (...) in adults. Persantin Retard and Asasantin Retard have been discontinued, but generic versions of modified-release dipyridamole with and without aspirin are available. Is this guidance up to date? . We found nothing new that affects the recommendations in this guidance. Next review : This guidance will be reviewed if there is new evidence that is likely to affect the recommendations. Guidance development process This guidance replaces NICE technology appraisal guidance on clopidogrel and modified-release

2010 National Institute for Health and Clinical Excellence - Technology Appraisals

117. Clopidogrel and proton pump inhibitors: interaction?updated advice

Clopidogrel and proton pump inhibitors: interaction?updated advice Clopidogrel and proton pump inhibitors: interaction—updated advice - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Clopidogrel and proton pump inhibitors: interaction—updated advice In light of the most recent evidence, the previous advice on the concomitant use of clopidogrel with proton pump inhibitors has now been modified. Use of either omeprazole or esomeprazole with clopidogrel should be discouraged (...) . The current evidence does not support extending this advice to other PPIs Published 11 December 2014 From: Therapeutic area: , Contents Article date: April 2010 Clopidogrel is indicated for the prevention of atherothrombotic events in patients who have had a myocardial infarction or ischaemic stroke, or who have established peripheral arterial disease. Combined with aspirin, the brand leader product (Plavix) may also be used to prevent atherothrombotic events in patients with acute coronary syndrome

2010 MHRA Drug Safety Update

118. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. (Abstract)

Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Variation in and irreversibility of platelet inhibition with clopidogrel has led to controversy about its optimum dose and timing of administration in patients with acute coronary syndromes. We compared ticagrelor, a more potent reversible P2Y12 inhibitor with clopidogrel in such patients.At randomisation, an invasive strategy was planned (...) for 13 408 (72.0%) of 18 624 patients hospitalised for acute coronary syndromes (with or without ST elevation). In a double-blind, double-dummy study, patients were randomly assigned in a one-to-one ratio to ticagrelor and placebo (180 mg loading dose followed by 90 mg twice a day), or to clopidogrel and placebo (300-600 mg loading dose or continuation with maintenance dose followed by 75 mg per day) for 6-12 months. All patients were given aspirin. The primary composite endpoint was cardiovascular

2010 Lancet Controlled trial quality: predicted high

119. Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis

Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

120. Clopidogrel non-responsiveness and risk of cardiovascular morbidity: an updated meta-analysis

Clopidogrel non-responsiveness and risk of cardiovascular morbidity: an updated meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.